Friess,
Langrehr,
Oettle,
Raedle,
Niedergethmann,
Dittrich,
Hossfeld,
St??ger,
Neyns,
Herzog,
Piedbois,
Dobrowolski,
Scheithauer,
Hawkins,
Katz,
Balcke,
Vermorken,
van Belle,
Davidson,
Esteve,
Castellano,
Kleeff,
Tempia-Caliera,
Kovar,
Nippgen,
- A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. Friess, H., Langrehr, J.M., Oettle, H., Raedle, J., Niedergethmann, M., Dittrich, C., Hossfeld, D.K., St??ger, H., Neyns, B., Herzog, P., Piedbois, P., Dobrowolski, F., Scheithauer, W., Hawkins, R., Katz, F., Balcke, P., Vermorken, J., van Belle, S., Davidson, N., Esteve, A.A., Castellano, D., Kleeff, J., Tempia-Caliera, A.A., Kovar, A., Nippgen, J. BMC Cancer (2006)